Theriva Biologics Future Growth
Future criteria checks 0/6
Theriva Biologics's earnings are forecast to decline at 4.5% per annum while its annual revenue is expected to grow at 95.3% per year. EPS is expected to grow by 22% per annum.
Key information
-4.5%
Earnings growth rate
22.0%
EPS growth rate
Biotechs earnings growth | 35.1% |
Revenue growth rate | 95.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 13 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -37 | N/A | N/A | 1 |
12/31/2025 | N/A | -35 | N/A | N/A | 1 |
12/31/2024 | N/A | -28 | N/A | N/A | 1 |
6/30/2024 | N/A | -22 | -18 | -18 | N/A |
3/31/2024 | N/A | -19 | -18 | -18 | N/A |
12/31/2023 | N/A | -18 | -19 | -19 | N/A |
9/30/2023 | N/A | -19 | -18 | -18 | N/A |
6/30/2023 | N/A | -21 | -19 | -19 | N/A |
3/31/2023 | N/A | -20 | -20 | -20 | N/A |
12/31/2022 | N/A | -20 | -19 | -19 | N/A |
9/30/2022 | N/A | -19 | -19 | -19 | N/A |
6/30/2022 | N/A | -17 | -16 | -16 | N/A |
3/31/2022 | N/A | -16 | -14 | -14 | N/A |
12/31/2021 | N/A | -23 | -13 | -13 | N/A |
9/30/2021 | N/A | -21 | -11 | -11 | N/A |
6/30/2021 | N/A | -20 | -11 | -11 | N/A |
3/31/2021 | N/A | -21 | -11 | -11 | N/A |
12/31/2020 | N/A | -13 | -12 | -12 | N/A |
9/30/2020 | N/A | -13 | -13 | -13 | N/A |
6/30/2020 | N/A | -15 | -14 | -14 | N/A |
3/31/2020 | N/A | -16 | -15 | -15 | N/A |
12/31/2019 | N/A | -16 | -14 | -14 | N/A |
9/30/2019 | N/A | -28 | -14 | -14 | N/A |
6/30/2019 | N/A | -26 | -14 | -14 | N/A |
3/31/2019 | N/A | -27 | -15 | -15 | N/A |
12/31/2018 | N/A | -25 | -17 | -17 | N/A |
9/30/2018 | N/A | -8 | -18 | -18 | N/A |
6/30/2018 | N/A | -22 | -19 | -19 | N/A |
3/31/2018 | N/A | -22 | N/A | -20 | N/A |
12/31/2017 | N/A | -22 | N/A | -20 | N/A |
9/30/2017 | N/A | -27 | N/A | -27 | N/A |
6/30/2017 | N/A | -18 | N/A | -28 | N/A |
3/31/2017 | N/A | -19 | N/A | -28 | N/A |
12/31/2016 | N/A | -27 | N/A | -28 | N/A |
9/30/2016 | N/A | -36 | N/A | -28 | N/A |
6/30/2016 | N/A | -34 | N/A | -38 | N/A |
3/31/2016 | N/A | -42 | N/A | -39 | N/A |
12/31/2015 | N/A | -44 | N/A | -39 | N/A |
9/30/2015 | N/A | -39 | N/A | -33 | N/A |
6/30/2015 | N/A | -37 | N/A | -22 | N/A |
3/31/2015 | N/A | -28 | N/A | -18 | N/A |
12/31/2014 | N/A | -20 | N/A | -16 | N/A |
9/30/2014 | N/A | -18 | N/A | -14 | N/A |
6/30/2014 | N/A | -16 | N/A | -11 | N/A |
3/31/2014 | N/A | -14 | N/A | -10 | N/A |
12/31/2013 | N/A | -12 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SFY0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SFY0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SFY0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SFY0 is forecast to have no revenue next year.
High Growth Revenue: SFY0 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SFY0's Return on Equity is forecast to be high in 3 years time